Navigation Links
Pinnacle Biologics Files for Orphan Drug Designation for PHOTOFRIN® in the Treatment of Patients with Malignant Mesothelioma.
Date:10/24/2011

BANNOCKBURN, Ill., Oct. 24, 2011 /PRNewswire/ -- Pinnacle Biologics, Inc., a privately held specialty bio-pharmaceutical company announced today that it has filed an Orphan Drug Designation (ODD) for their product PHOTOFRIN® (porfimer sodium) as adjuvant therapy to surgery in the treatment of Malignant Pleural Mesothelioma.

Malignant Pleural Mesothelioma is a form of cancer affecting the lining of the lungs. It is a rare, highly aggressive and devastating cancer with a poor prognosis. The incidence of Malignant Pleural Mesothelioma has been linked to previous asbestos exposure and has grown from almost zero to approximately 3,000 new cases each year in the United States.(1)

"We are pleased to file for the Orphan Drug Designation of PHOTOFRIN® and potentially for its utilization in Mesothelioma," said Guillermo Herrera, Executive Chairman of Pinnacle Biologics. "Presently, the treatments for Mesothelioma are palliative at best, and the outcome in patients with Malignant Pleural Mesothelioma is very poor.  Pinnacle is committed to support the approval and expand the use of PHOTOFRIN® into new indications such as Malignant Pleural Mesothelioma, where preliminary clinical results are very encouraging."

According to Joseph S. Friedberg, MD, Chief, Section of Thoracic Surgery - Penn Presbyterian Medical Center; Co- Director, Penn Mesothelioma and Pleural Disease Program at Penn Medicine, "In studies completed at Penn, photodynamic therapy (PDT), in conjunction with surgery, has shown some very promising results for the treatment of mesothelioma, a highly lethal cancer of the chest cavity lining.  By utilizing PDT as an intraoperative treatment, we have been able to develop a technique where we can reliably preserve the patient's lung. When compared to other treatments, this combination of lung-sparing surgery, PDT and standard chemotherapy appears to have a positive impact on both survival and quality of life. Based upon our clinical observations, characterizing the PDT effect and working on techniques to magnify it has become a major focus of our research. "

About Photodynamic therapy (PDT) and PHOTOFRIN®

Photodynamic therapy (PDT) with PHOTOFRIN® is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN®. Illumination with non-burning laser light 40–50 hours following injection with PHOTOFRIN® constitutes the second stage of therapy. When injected, PHOTOFRIN® is attracted to and linger in certain tissues, especially cancer cells, and tumor destruction is by biochemical reactions, not by heat.  Tumor selectivity occurs through a combination of preferential retention of PHOTOFRIN® by the tumor and selective delivery of light to the tumor site.

A novel therapeutic technique, PHOTOFRIN® is FDA approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The product is available in the USA, several major European countries, Japan, several Latin American and Southeast Asian markets. Additional approved indications for PHOTOFRIN® include high-grade dysplasia (HGD) in Barrett's esophagus (BE) in North America and papillary bladder cancer in Canada and Argentina.

For additional information about PHOTOFRIN®, please see full prescribing information available at www.photofrin.com.

About Non-Small Cell Lung Cancer(2)

Lung cancer is the leading cause of cancer death in men and women. There are more than 200,000 patients with lung cancer each year. NSCLC is the most common type of lung cancer. It usually grows and spreads more slowly than small cell lung cancer.

There are several types of NSCLC including adenocarcinoma and squamous cell carcinoma. All can be treated with PDT at any stage.

About Esophageal Cancer(3)

Esophageal cancer (EC) forms in tissues lining the esophagus (the muscular tube through which food passes from the mouth to the stomach). There are two types of EC: squamous cell carcinoma and adenocarcinoma. Both types of cancer can be treated with PDT.

It is difficult to determine specific causes of EC. People with certain risk factors, however, are more likely to develop esophageal cancer. These risk factors include male gender, age 65 or older, smoking and heavy alcohol consumption. In 2010, there were approximately 16,600 new cases of EC and 14,500 deaths in the United States.

References:

  1. American Cancer Society - Malignant Mesothelioma Web Site http://www.cancer.org/Cancer/MalignantMesothelioma
  2. National Center for Biotechnology Information –  PubMed Web Site http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004462
  3. National Cancer Institute – Web Site http://www.cancer.gov/cancertopics/types/esophageal

About Pinnacle Biologics, Inc.

Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.

This press release was funded by Pinnacle Biologics, Inc.  Dr. Joseph S. Friedberg has no financial relationship with Pinnacle Biologics Inc. This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Pinnacle intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21W of the Private Securities Litigation Reform Act of 1995.

CONTACT:

Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

www.pinnaclebiologics.com

www.photofrin.com

PHOTOFRIN® is a trademark of Pinnacle Biologics Inc.


'/>"/>
SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pinnacle Oncology LLC Acquires Rights to Unique Radioprotector From the University of Chicago
2. Pinnacle Biologics Appoints ALKOPHARMA SA Its Exclusive Distributor For PDT (Photodynamic Therapy), in Select European Countries, Middle East And South East Asian Territories
3. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
4. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
5. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
6. CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
7. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
8. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
9. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
10. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
11. Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):